Tango Therapeutics Inc (TNGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tango Therapeutics Inc (TNGX) has a cash flow conversion efficiency ratio of -0.038x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.87 Million) by net assets ($1.02 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Tango Therapeutics Inc for the company's overall valuation and market capitalisation.
Tango Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tango Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tango Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tango Therapeutics Inc ranked by their cash flow conversion efficiency. Explore TNGX cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chenzhou Jingui Silver Industry Co Ltd
SHE:002716
|
0.008x |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332
|
0.044x |
|
GRUPO SIM. S.A.B. B ADR/3
F:GSM
|
-0.007x |
|
Just Eat Takeaway
AS:TKWY
|
0.039x |
|
Cadence Bancorp
NYSE:CADE
|
0.031x |
|
Kumba Iron Ore Ltd
JSE:KIO
|
0.139x |
|
Hui Lyu Ecological Technology Groups Co Ltd
SHE:001267
|
-0.026x |
|
Yifeng Pharmacy
SHG:603939
|
0.055x |
Annual Cash Flow Conversion Efficiency for Tango Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tango Therapeutics Inc from 2019 to 2025. View latest Tango Therapeutics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $346.18 Million | $-138.89 Million | -0.401x | +39.13% |
| 2024-12-31 | $199.52 Million | $-131.50 Million | -0.659x | -41.40% |
| 2023-12-31 | $253.11 Million | $-117.98 Million | -0.466x | -6.61% |
| 2022-12-31 | $249.48 Million | $-109.08 Million | -0.437x | -153.22% |
| 2021-12-31 | $344.75 Million | $-59.53 Million | -0.173x | -109.51% |
| 2020-12-31 | $38.60 Million | $70.07 Million | 1.815x | +157.86% |
| 2019-12-31 | $7.91 Million | $-24.80 Million | -3.138x | -- |
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more